Regulation of intracellular pH (pH i ) and H + efflux were investigated in Trypanosoma brucei bloodstream and procyclic trypomastigotes using the fluorescent dyes 2h,7h-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) acetoxymethyl ester and free BCECF respectively. pH i in bloodstream and procyclic trypomastigotes was 7.47p0.06 and 7.53p0.07 respectively. Differences in the mechanisms for the regulation of pH i were noted between bloodstream and procyclic forms. Procyclic trypomastigotes maintained their pH i at neutral over a wide range of external pH values from 6 to 8, and in the absence of K + or Na + . The H + -ATPase inhibitors N,Nh-dicyclohexylcarbodi-imide (DCCD), diethylstilboestrol and N-ethylmaleimide substantially decreased the steady-state pH i and inhibited its recovery from acidification. The rate of H + efflux in these forms was determined to be 62p6.5 nmol\min per mg of protein, and was substantially decreased by H + -ATPase inhibitors. The data support the presence of an H + -ATPase as the major regulator of pH i in procyclic trypomastigotes. In contrast, bloodstream trypomastigotes were unable to maintain a neutral pH under acidic conditions, and their steady-state pH i and recovery from acidification were unaffected by H + -ATPase inhibitors, except for DCCD (100 µM). Their steady-state pH i was markedly decreased in glucose-free buffer or by 10 mM pyruvate, whereas procyclic
INTRODUCTION
Trypanosoma brucei, a protozoan parasite transmitted by the tsetse fly in sub-Saharan Africa, is the aetiologicol agent of African sleeping sickness in humans and nagana in cattle. T. brucei has a complex life cycle involving several morphological and functionally different stages that adapt to a variety of conditions imposed by the insect vector and mammalian host environments. The procyclic stage replicates within the alimentary tract of the tsetse fly, where the environmental (external) pH (pH e ) is acidic [1] , whereas the bloodstream form propagates in the host's blood, where the pH e is consistently 7.4. Marked differences in metabolism between the two stages have evolved as a result of the very different environments in which they reside. In the host's bloodstream, the concentration of glucose is relatively constant (approx. 5 mM), and energy generation by the bloodstream form occurs exclusively via glycolysis. Glucose enters bloodstream trypomastigotes through a facilitateddiffusion transporter independent of a proton motive force, and glycolysis takes place in a unique organelle, the glycosome [2] [3] [4] [5] [6] [7] . The end-product of glycolysis in bloodstream trypomastigotes is pyruvate, which is excreted by a facilitated-diffusion pyruvate Abbreviations used : BCECF, 2h,7h-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein ; α-CHC, α-cyanohydroxycinnamic acid ; DCCD, N,Nh-dicyclohexylcarbodi-imide ; DES, diethylstilboestrol ; EIPA, 5-(N-ethyl)-N-isopropylamiloride ; H 2 DIDS, 4,4h-di-isothiocyanatodihydrostilbene-2,2h-disulphonic acid ; LDH, lactate dehydrogenase ; NEM, N-ethylmaleimide ; pH e , external pH ; pH i , intracellular pH. 1 To whom correspondence should be addressed (e-mail rodoc!uiuc.edu).
trypomastigotes were unaffected by similar treatments. The rate of H + efflux in bloodstream trypomastigotes was 534p38 nmol\ min per mg of protein, and was decreased in the absence of glucose and by the addition of pyruvate or DCCD. Pyruvate efflux in these forms was calculated to be 499p34 nmol\min per mg of protein, and was significantly inhibited by DCCD, 4,4h-diisothiocyanatodihydrostilbene-2,2h-disulphonic acid and α-cyanohydroxycinnamic acid. The pyruvate analogues β-hydroxypyruvate, 3-bromopyruvate, 3-oxoglutarate, oxaloacetate, 3-oxoisovalerate and 3-oxoisohexanoate significantly decreased pH i , as well as proton and pyruvate efflux, whereas lactate had only a small effect, and no effect was observed with citrate or fumarate. The inhibition by pyruvate analogues of pyruvate efflux, proton efflux and acidification of pH i supports the hypothesis that pyruvate efflux is accompanied by proton efflux and that this is the major pH i control mechanism in bloodstream forms. Inhibition by H + -ATPase inhibitors of residual H + efflux in the absence of glucose or in the presence of high extracellular pyruvate indicates a minor role for H + -ATPase(s) in control of pH i in bloodstream forms.
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carrier [8] [9] [10] . In the procyclic trypomastigote, the major metabolic substrates are amino acids and glucose, which may be taken up via an active transport mechanism driven by the proton motive force. Conventional glycolysis and oxidative phosphorylation occur [11] . Although a pyruvate transporter is present in the procyclic form, pyruvate release is over 100-fold slower than for bloodstream forms due to its further metabolism inside the mitochondrion [12] . The ability of T. brucei to regulate its intracellular pH (pH i ) throughout its life cycle is critical to its survival, as most intracellular enzymes function optimally within a narrow pH range. In most higher-eukaryotic cells whose environment is neutral, metabolically generated protons are exchanged for Na + via a Na + \H + antiporter [13] . The sodium gradient generated by the Na + \K + -ATPase drives this exchange. However, at low pH e , Na + \H + exchange is unfavourable and therefore cells that maintain a pH i more alkaline than their environment frequently utilize ATP-driven proton pumps to regulate their pH i . Proton pumping is electrogenic and is usually supported by one or more anion-or cation-conductive pathways that serve to partially dissipate the membrane potential, thereby increasing the efficiency of the pump. In addition, the proton motive force generated by these pumps frequently drives nutrient uptake in these cells.
Previous studies in the procyclic form of T. brucei using the pH-sensitive dye 2h,7h-bis-(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF) reported a steady-state pH i of 7.05 [14] or 7.22 [15] , suggesting that this stage maintains a pH i that is more alkaline than its environment. In addition, Fraser-L'Hostis et al. [15] found that the pH i of procyclics remained neutral in acidic and alkaline conditions, and was sensitive to the H + -ATPase inhibitor N,Nh-dicyclohexylcarbodi-imide (DCCD), supporting a major role for an H + -ATPase in this stage. They also proposed that regulation of pH i in procyclics may be linked to HCO $ − and is due in part to an amiloride-sensitive Na + \H + exchanger.
The steady-state pH i of T. brucei bloodstream forms has been investigated by a number of researchers. Using "%C-labelled 5,5-dimethyloxazolidine-2,4-dione or ["%C]methylamine, pH i was calculated to be 7.01 by Thissen and Wang [16] , and 7.2 by Nolan and Vooheis [17, 18] . Using BCECF, the steady-state pH i was determined to be 7.08 by Ruben et al. [19] , and 7.4 by both Scott et al. [14] and Fraser-L'Hostis et al. [15] . Thus bloodstream forms appear to maintain a pH i equivalent to or slightly more acidic than the pH of their environment in the bloodstream.
There have been limited studies of the regulation of pH i in T. brucei bloodstream forms. Thissen and Wang [16] noted that the protonophore carbonyl cyanide m-chlorophenylhydrazone (' CCCP ') had little effect on the pH i of bloodstream forms at pH 7.4, but a major effect at pH 6.0. This suggests a passive control mechanism at physiological pH e , but potentially the function of a proton pump in acidic environments, such as the mid-gut of the tsetse fly. They also noted that millimolar concentrations of the ATPase inhibitor N-ethylmaleimide (NEM) had no effect on pH i in bloodstream forms. Ter Kuile et al. [20] also suggested that an energy-dependent pump may be needed for maintenance of pH i in an acidic environment, but not under physiological conditions in the host. Furthermore, they noted that, at 37 mC, pH i was not regulated when pH e was varied, whereas at 22 mC the pH i remained constant. Fraser-L 'Hostis et al. [15] found the pH i of bloodstream forms to be slightly acidified after treatment with the H + -ATPase inhibitors DCCD and NEM, or with the anion blocker 4,4h-di-isothiocyanatodihydrostilbene-2,2h-disulphonic acid (H # DIDS) or the Na + \H + antiport inhibitor 5-(N-ethyl)-N-isopropylamiloride (EIPA), suggesting that three mechanisms, namely an H + -ATPase, a HCO $ − -dependent anionic pathway and a Na + \H + exchanger, may play a role in the regulation of pH i in these forms. These workers also showed that the addition of pyruvate led to rapid cytosolic acidification, suggesting the possibility that pyruvate is co-transported with protons.
Despite these previous studies, the mechanisms that are important in the regulation of pH i in T. brucei remain unclear. These findings do suggest, however, that there may be significant differences in the regulation of pH i in procyclic compared with bloodstream forms. If protons accompany pyruvate efflux in bloodstream forms, then the monocarboxylate (pyruvate) carrier may play a substantial role in the regulation of pH i in this stage. In procyclics, pyruvate production, being at a low level, is unlikely to contribute significantly to pH i regulation. To investigate further the regulation of pH i in T. brucei bloodstream and procyclic forms and to examine the role of the pyruvate carrier in bloodstream forms, we undertook studies involving pH i determination and proton and pyruvate efflux measurements as a function of the ionic composition of the medium, under acid loads, and in the presence of different inhibitors. We conclude that an H + -ATPase supported by chloride-conductive pathways regulates pH i in both procyclic and bloodstream forms, and that a pyruvate-proton symport plays a significant role in the regulation of pH i in bloodstream trypomastigotes.
MATERIALS AND METHODS

Culture methods
T. brucei bloodstream forms (monomorphic strain 427 from clone MITat 1.4, otherwise known as variant 117) were isolated from infected mice or rats using a DEAE-cellulose column and resuspended in ice-cold phosphate buffer at pH 8.0 [21] . The same strain of bloodstream form was also grown axenically at 37 mC in HMI-9 medium [22] and used in a limited number of experiments to confirm the results obtained with trypomastigotes isolated from rats. T. brucei procyclic forms were grown at 28 mC in medium SDM-79 supplemented with 10 % (v\v) heatinactivated fetal calf serum [23] . After 2 or 3 days of inoculation, cells were collected by centrifugation (1500 g for 10 min) and washed twice in Dulbecco's PBS, pH 7.5. Procyclic trypomastigotes of strain ILTar 1 were used for all studies reported. Additionally, procyclics transformed from the bloodstream strain described above were used for a limited number of experiments to confirm that differences in pH i regulation were stage-but not strain-related. pH i measurements pH i was measured fluorimetrically using BCECF. After harvesting the cells, they were centrifuged as before and resuspended to a final density of 1i10) cells\ml in loading buffer containing 0.1 µM BCECF acetoxymethyl ester. The suspensions were incubated for 30 min on ice. Subsequently the cells were washed twice with standard buffer to remove the extracellular dye and pH regulation in Trypanosoma brucei resuspended in buffer A (procyclics) or separation buffer, pH 7.5 [21] (bloodstream forms) to a final density of 1i10) cells\ml and kept on ice. For pH i measurements, a 500 µl (bloodstream forms) or 250 µl (procyclic forms) aliquot of the cell suspension was centrifuged and resuspended into 2.5 ml of the appropriate buffer (final densities 2i10( and 1i10( cells\ml respectively) in a cuvette placed in a thermostatically controlled Hitachi F-2000 spectrofluorimeter at 30 mC for procyclics or at 37 mC for bloodstream forms. The fluorescence ratio, with wavelengths for excitation set at 505\440 nm and for emission at 530 nm, were recorded and translated into pH values on the basis of the ratios obtained at various pH values, as described previously [24] . Acid loading was accomplished by preincubating 1.5i10( cells in 60 µl of buffer containing 40 mM NH % Cl at 30 mC for 15 min (NH % + prepulse technique). Parasites were then centrifuged as before and resuspended in various buffers with or without inhibitors. The recovery rate was calculated from the slope of the trace in the initial 60 s of recovery, and the final pH i was determined after 10 min. Traces shown are representative of at least three independent experiments conducted on separate cell preparations.
Chemicals and solutions
Pyruvate efflux measurements
Pyruvate efflux was measured by following NADH oxidation at 340-430 nm using a dual-wavelength spectrophotometer (Aminco DW2000). A total of 2.5i10( (250 µl) T. brucei bloodstream forms were preincubated in separation buffer [21] at 37 mC for 5 min before each experiment, centrifuged as before and resuspended in 2.5 ml of assay buffer, which consisted of standard buffer plus 10 mM glucose, 200 µM NADH and 10 units of LDH at 37 mC. Pyruvate efflux was followed for 10 min, and inhibitors were added after 5 min. To rule out inhibition of LDH by the inhibitors, 100 nmol of pyruvate was added to the cuvette at the conclusion of each experiment. The pyruvate analogues 3-bromopyruvate and oxaloacetate were found to behave as substrates for LDH. To measure inhibition of pyruvate efflux by these analogues, parasites were preincubated for 5 min with the analogue, centrifuged and immediately resuspended in assay buffer, and pyruvate efflux was measured during the first 60 s. Calibration was performed using 100 nM increments of pyruvate. Traces shown are representative of at least three independent experiments conducted on separate cell preparations.
Proton efflux measurements
To measure pH e reflecting proton pumping by parasites, 2.5i10( parasites were washed and resuspended in a weakly buffered (0.1 mM Hepes\Tris) standard buffer solution containing 0.38 µM BCECF (free acid) at 37 mC for bloodstream forms and at 30 mC for procyclics. The fluorescence ratio, with wavelengths for excitation set at 505\440 nm and for emission at 530 nm, were recorded and translated into H + \min values on the basis of ratios obtained by the addition of known equivalents of HCl [25] . Traces shown are representative of at least three independent experiments conducted on separate cell preparations.
ATP measurements
Portions of 5i10( cells in 1 ml of standard buffer were incubated with each inhibitor for 10 min at 37 mC with agitation. The cells were then centrifuged at 8500 g for 5 min at 4 mC and the supernatant removed. The pellet was freeze-thawed five times and diluted with 25 mM Hepes, pH 7.8, to a total volume of 475 µl, and then incubated with 5 % trichloroacetic acid for 15 min on ice. The suspension was then centrifuged at 8500 g for 5 min and the supernatant removed. A 5 µl sample of the supernatant was diluted 1 : 40 (v\v) in 25 mM Hepes buffer and added to 200 µl of luciferin\luciferase reagent in a cuvette, and the chemiluminescence was recorded in a TD 20\20 luminometer (Turner Designs, Sunnyvale, CA, U.S.A.). Calibration was performed by the incremental addition of ATP to parallel samples.
Data analysis
All results are expressed as meanspS.D. for n independent experiments. Statistical significance was determined by Student's t test. Significance was considered at a level of P 0.05.
RESULTS
Effects of Na + , K + and Cl − on steady-state pH i and recovery from acidification
The mean baseline pH i of procyclics and bloodstream trypomastigotes in the nominal absence of bicarbonate and at a pH e of 7.4 in standard buffer was 7.53p0.06 and 7.47p0.07 respectively (Table 1) . Procyclics were able to maintain their pH i within 0.6 pH units in standard buffer over a range of pH e values of 6.0-8.0 (Figure 1 ). Bloodstream forms were unable to maintain a neutral pH i at non-physiological pH e , with pH i ranging from 6.71 at pH e 6.0 to 7.93 at pH e 8.0 (Figure 1 ). These data suggest that procyclics are better than bloodstream forms at regulating their pH i against a pH gradient, which might be expected given the very different environments in which the two stages reside.
The contributions of the ions Na + , K + and Cl − to the maintenance of pH i in T. brucei were determined by measuring steady-state pH i and recovery of pH i following acidification in specific ion-free buffers as compared with standard buffer. The absence of Na + or K + from the buffer had no effect on the pH i of either procyclic ( Figure 2A ; Table 1 ) or bloodstream ( Figure  2B ; Table 1 ) trypomastigotes. When Na + was replaced by choline (Na + -free buffer), a rise of 0.18 pH unit in the final pH i was noted in bloodstream forms, but this was not found in Na + -free NMG buffer ( Figure 2B ; Table 1 ). Furthermore, the proton efflux rate of neither stage was decreased in Na + -free buffer (results not shown). These results suggest that Na + and K + are not required for the maintenance of steady-state pH i in either stage, ruling out a significant role for a Na + \H + antiport or Na + -dependent anion exchanger in the regulation of pH i , contrary to a previous report [15] . EIPA (100 µM), an inhibitor of Na + \H + exchangers, caused a slight but significant decrease in the steady-state pH i of procyclic, but not bloodstream, forms (Table 2 ). In acidified procyclic trypomastigotes, but not in bloodstream trypomastigotes, EIPA caused a dose-dependent decrease in the final pH i , but not in the rate of pH i recovery (results not shown). Although these data apparently support the involvement of a Na + \H + exchanger in the regulation of pH i in procyclics, the lack of a requirement for Na + suggests that EIPA may be having some other effect. We demonstrated recently that EIPA behaves as a protonophore in T. cruzi amastigotes and trypomastigotes [26] , as has been described in other cells [27] , and a similar effect may be occurring here. The steady-state pH i in the absence of Cl − was decreased by 0.25 and 0.18 pH unit in procyclic and bloodstream forms respectively (Table 1 ). These cells rapidly recovered toward their original pH i when centrifuged and resuspended in standard buffer (results not shown). Acidified procyclic ( Figure 2A ) and bloodstream ( Figure 2B ) forms suspended in Cl − -free buffer recovered their pH i almost at the same rate as controls, and the final pH i attained was 0.28 and 0.19 pH unit lower respectively. These data support a role for Cl − in the maintenance of pH i in T. brucei, where it is likely to function to support electrogenic pumping, as has been observed in other trypanosomatids [24, [28] [29] [30] [31] . The addition of 25 mM HCO $ − reduced the acidification that resulted from suspension in Cl − -free buffer in both stages (results not shown). No significant effect of HCO $ − was observed in either stage on steady-state pH i in standard buffer at pH 7.4 (results not shown). However, at pH e 6, HCO $ − increased pH i from 6.71 to 7.07 in bloodstream forms (results not shown). To investigate the possible presence of an Na + -dependent or -independent Cl − \HCO $ − exchanger, the inhibitor H # DIDS was used at concentrations up to 0.5 mM. Even though no effect was noted on the pH i of procyclics, they rapidly became clumped (but remained motile) after a few minutes ' exposure to concentrations of H # DIDS of 250 µM or more. In bloodstream forms, 0.5 mM H # DIDS decreased the steady-state pH i (Table 2 ) pH regulation in Trypanosoma brucei and the final pH i after recovery from acidification, but did not reduce the rate of recovery following acidification (results not shown). The lack of inhibition by H # DIDS, in addition to the data demonstrating the maintenance of steady-state pH i and normal recovery from acidification in the absence of Na + or HCO $ − in procyclic trypomastigotes, suggests that a Cl − \ HCO $ − exchanger is not a significant regulator of pH i in T. brucei procyclic forms.
Effects of H + -ATPase inhibitors on steady-state pH i and recovery from acidification
The effects of various H + -ATPase inhibitors on pH i were determined in parasites at steady state and following acidification. The general H + -ATPase inhibitors DCCD (100 µM) and NEM (1 mM) and the plant and yeast H + -ATPase inhibitor DES (100 µM), as well as the V-type H + -ATPase inhibitor bafilomycin A " (2 µM), all markedly acidified the steady-state pH i of procyclic forms (Table 2) . Furthermore, these inhibitors decreased the rate of recovery of pH i in acidified procyclics in a dose-dependent manner ( Figures 3A-3D) . In bloodstream forms both the steadystate pH i (Table 2 ) and the recovery of pH i following acidification were significantly decreased by 100 µM DCCD ( Figure 3A) , but not by up to 100 µM DES ( Figure 3B ), 1 mM NEM ( Figure 3C ) or 5 µM bafilomycin ( Figure 3D ). In addition, there was no effect on the pH i of either stage by 250 µM omeprazole, an inhibitor of gastric H + \K + -ATPase, or 1 mM ouabain, an inhibitor of the Na + \K + -ATPase (Table 2 ). Limited studies on pH i in axenically grown bloodstream forms and in procyclics transformed from bloodstream forms confirmed these results, supporting the conclusion that the differences observed were stage-related (results not shown). Intracellular ATP levels were determined, to rule out inhibitor effects resulting from decreased ATP levels. ATP levels as a percentage of control in procyclics and bloodstream forms respectively were 96 % and 92 % for 100 µM NEM, 69 % and 61 % for 100 µM DCCD, 73 % and 84 % for 50 µM DES and 85 % and 89 % for 0.5 mM H # DIDS. Together these results are consistent with the hypothesis that an H + -ATPase is the major regulator of pH i in T. brucei procyclic forms, but not in bloodstream forms.
Effects of inhibitors on proton efflux
Proton efflux was calculated to be 62p6.5 nmol\min per mg of protein in procyclics, and 534p38 nmol\min per mg in bloodstream forms (n l 3). In procyclic forms, 25 µM DCCD, 25 µM DES or 50 µM NEM almost completely abolished proton pumping, while 2 µM bafilomycin decreased it by 29 % (Figure  4 ). In bloodstream forms, 100 µM DCCD, 50 µM DES and 1 mM NEM decreased proton efflux by 56 %, 17% and 8 % respectively (results not shown). These data show that proton efflux in procyclics appears to be entirely the result of H + - ATPases. In bloodstream forms, where proton efflux was almost 10-fold higher than in procyclics, only a small percentage could be attributed to H + -ATPases. This suggests that H + -ATPases are present in the plasma membrane of bloodstream forms, but that their overall contribution to proton pumping is minor. The substantial difference in the magnitude of the inhibition by DCCD compared with that by DES or NEM suggests that DCCD may be affecting proton efflux by another mechanism in addition to inhibition of H + -ATPases.
Figure 4 Effects of H + -ATPase inhibitors on proton efflux of procyclic forms
Contribution of metabolism to regulation of pH i
Since there are major differences in metabolism between procyclics and bloodstream forms, we examined whether these
Figure 5 Effect of glucose on the pH i of bloodstream forms
Bloodstream forms were suspended in standard buffer with or without 10 mM glucose (A), or acidified, centrifuged and resuspended in standard buffer with or without glucose and allowed to recover their pH i (B). Glucose at 10 mM (Glc) was added at the times indicated by the arrows. Traces shown are from typical experiments. differences contributed to the regulation of pH i in bloodstream forms. When resuspended in glucose-free standard buffer, bloodstream forms rapidly acidified to pH i 7.16p0.08 ( Figure 5A) , whereas the pH i of procyclics remained similar to that of controls (results not shown). Parasites remained motile during this period of glucose depletion. The subsequent addition of glucose to bloodstream forms resulted in a further drop in pH i to 7.02p0.05, followed by recovery to the same pH i as controls ( Figure 5A ). Acidified bloodstream forms recovered their pH i more slowly in glucose-free buffer as compared with controls, and the final pH i attained was 7.14p0.12 ( Figure 5B ). The non-metabolizable glucose analogues 6-deoxy--glucose and 2-deoxy--glucose, when substituted for glucose, had no effect on pH i , ruling out the presence of a proton-glucose symport as the cause of the initial decrease in pH observed following the addition of glucose (results not shown). Additionally, incubation in a glucose-free buffer significantly reduced proton efflux by 54 % to 246p24 nmol\min per mg of protein in bloodstream forms, but not in procyclics ( Figure 6A , trace a ; and results not shown). These data suggest that glucose metabolism is linked to the regulation of pH i and the rate of proton efflux in bloodstream forms.
Role of the pyruvate transporter in regulation of pH i
The addition of pyruvate to bloodstream forms has been shown previously to result in cytosolic acidification [15] . Pyruvate efflux in bloodstream forms appears to occur by facilitated diffusion through a monocarboxylate (pyruvate) transporter [8] [9] [10] . Previously identified monocarboxylate transporters in bacteria, yeast and mammalian cells transport substrates bidirectionally down their concentration gradient in symport with protons, and have an affinity for a limited repertoire of carboxylic acids [32] [33] [34] [35] [36] . To investigate the relationship between pyruvate efflux and regulation of pH i , inhibitors of pyruvate efflux, including pyruvate and various carboxylic acids that compete with pyruvate for the transporter, as well as the mitochondrial pyruvate transport inhibitor α-CHC, were examined for their effects on pH i and on proton and pyruvate efflux.
The addition of 10 mM pyruvate to bloodstream forms in the presence of glucose caused rapid acidification, followed by a slow recovery to near-control levels, while a concentration of pH regulation in Trypanosoma brucei 
Figure 7 Effect of pyruvate on the pH i of bloodstream forms
Bloodstream forms were suspended in standard buffer (A) or acidified, centrifuged and resuspended in standard buffer and allowed to recover their pH i (B). Pyruvate was added at the time indicated by the arrows at 10 mM (10) or 25 mM (25) (A), or was present in the resuspension medium at the concentrations indicated (B). Traces shown are from typical experiments.
25 mM or more resulted in rapid acidification to pH 7.09p0.09 (Table 3) , without recovery ( Figure 7A ). Pyruvate also inhibited recovery from acidification in a dose-dependent manner in bloodstream forms ( Figure 7B ). Pyruvate at 25 mM did not induce further acidification in bloodstream forms already acidified by suspension in glucose-free buffer (results not shown). Procyclics were unaffected by 25 mM pyruvate and mildly acidified by 25-50 mM pyruvate (Table 3) . These data strongly suggest that pyruvate in bloodstream forms is transported in symport with protons.
In the absence of glucose, pyruvate had no significant effect on proton efflux by bloodstream forms ( Figure 6B, trace b) . The addition of 100 µM DCCD to parasites suspended in glucosefree buffer reduced proton efflux by 73 %, to 136p11 nmol\min per mg of protein ( Figure 6B, trace a) . In the presence of glucose, the proton efflux rate in bloodstream forms was decreased by 25 mM pyruvate by 37 %, to 314p21 nmol\min per mg of protein ( Figure 6C, traces a and b) , but was not changed in procyclic forms (results not shown). The addition of both DCCD and pyruvate to bloodstream forms suspended in standard buffer substantially reduced proton efflux by 89 %, to 56p12 nmol\min per mg of protein ( Figure 6C, trace a) . Furthermore, the addition of 1 mM NEM or 50 µM DES substantially reduced proton efflux further in the absence of glucose to 219p24 and 198p19 nmol\min per mg of protein respectively, and in the presence of 25 mM pyruvate to 232p14 and 213p30 nmol\min per mg respectively. These data support the existence of two major mechanisms for proton efflux in bloodstream forms.
Pyruvate efflux in bloodstream forms has been shown previously to be inhibited by a number of pyruvate analogues [8, 9] . The steady-state pH i of bloodstream forms was significantly lowered by 10 mM oxaloacetate, 3-oxoglutarate, 3-oxoisovalerate (Table 3) , 3-bromopyruvate or β-hydroxypyruvate (results not shown). Lactate at 25 mM slightly acidified bloodstream forms. However, pH i was not affected by 25 mM citrate or 10 mM fumarate (results not shown). The steady-state pH i of procyclics was not affected significantly by any of the compounds tested at concentrations of 10 mM (Table 3) . 3-Bromopyruvate at 10 mM significantly decreased the pH i of bloodstream forms to 6.89p0.12. Proton pumping in bloodstream forms was also significantly inhibited by 10 mM oxaloacetate, 3-oxoglutarate, 3-
Table 4 Effects of various compounds on proton and pyruvate efflux in bloodstream forms
Bloodstream forms were suspended in 0.1 mM Hepes/Tris standard buffer for proton efflux. or in the assay buffer described in the Materials and methods section for pyruvate efflux. Inhibitors were added 60-120 s after the start of each 10 min determination, and the rate of efflux was calculated before and after addition of inhibitors. For pyruvate efflux determinations using oxaloacetate, parasites were preincubated for 5 min at 37 mC with the inhibitor, centrifuged and resuspended in assay buffer, and the rate was determined for the first 60 s (see the Materials and methods section). Results shown are meanspS.D. of a minimum of three experiments. n.d., not determined. Significance of differences compared with control : *P 0.05. (Table 4) and 10 mM 3-oxoisohexanoate (results not shown). Citrate or fumarate at 25 mM had no effect on proton efflux (results not shown), whereas 10 mM 3-bromopyruvate significantly decreased it to 197p54 nmol\min per mg. The rate of pyruvate efflux was calculated to be 499p 34 nmol\min per mg. Pyruvate efflux in bloodstream forms was significantly inhibited by 10 mM oxaloacetate, 3-oxoglutarate, 3-oxoisovalerate or β-hydroxypyruvate, 25 mM lactate (Table 4 ) and 10 mM 3-oxoisohexanoate (results not shown). 3-Bromopyruvate at 10 mM decreased pyruvate efflux to 45p34 nmol\min per mg, whereas 25 mM citrate or fumarate had no effect (results not shown). A strongly positive correlation pH regulation in Trypanosoma brucei Tables 3 and 4 . Agents used were 25 mM lactate (LAC), 10 mM 3-oxoglutarate (GLUT), 10 mM 3-oxoisovalerate (VAL), 2 mM α-CHC (CHC), 10 mM oxaloacetate (ACET) and 10 mM β-hydroxypyruvate (OHPYR).
was calculated between the inhibition of pyruvate efflux and both the decrease in pH i (r# l 0.71) and the inhibition of proton efflux (r# l 0.83) in bloodstream forms (Tables 3 and 4 ; Figure 8 ), supporting the contention that pyruvate efflux is accompanied by proton efflux in bloodstream forms.
The mitochondrial pyruvate carrier inhibitor α-CHC has been shown by some investigators [9] , but not others [10] , to inhibit pyruvate efflux in T. brucei bloodstream forms. The addition of 2 mM α-CHC resulted in a decrease in pH i and prevented full recovery from acidification in bloodstream forms, and a concentration of 4 mM had a similar effect on procyclics (Table  3) . α-CHC also decreased proton and pyruvate efflux in bloodstream forms and proton efflux in procyclic forms (Table 4 and results not shown). Because α-CHC appears to affect both procyclics and bloodstream forms, it is unclear if it is affecting the plasma membrane pyruvate carrier or some other metabolic pathway, such as the mitochondrial pyruvate transporter, in procyclics.
We showed that DCCD has a significant effect on pH i (Table  2 ) and recovery from acidification ( Figure 3A ) in bloodstream trypomastigotes, as compared with other H + -ATPase inhibitors (Table 2 ; Figures 3B-3D ). We also demonstrated that DCCD affects both the glucose-sensitive ( Figure 6C ) and the glucoseinsensitive ( Figure 6B ) portion of proton efflux. These data suggested that DCCD may be inhibiting the pyruvate transporter in addition to the H + -ATPase. We found that the addition of 100 µM DCCD significantly reduced pyruvate efflux by 77 %, to 144p23 nmol\min per mg of protein ( Figure 9A ). The addition of pyruvate to the assay following addition of DCCD produced a decrease in absorbance of similar magnitude when compared with controls, demonstrating that LDH in the assay buffer was not being inhibited by DCCD ( Figure 9A ). We also observed that H # DIDS had a significant effect on the pH i of bloodstream, but not procyclic, forms (Table 2 ). Stilbene derivatives have been shown to be inhibitory for mammalian monocarboxylate carriers [13] , and we suggest that a similar effect may be occurring here. We found that pyruvate efflux was decreased by 34 % to 330p39 nmol\min per mg of protein in the presence of 500 µM H # DIDS (results not shown). These data suggest that much of the effect of DCCD and H # DIDS on the pH i of bloodstream forms may be due to direct inhibition of the pyruvate transporter.
Previously it has been argued that, if the downhill transport of pyruvate is coupled with protons, the inward-directed proton motive force would significantly slow down pyruvate efflux, leading to cytosolic acidification [20] . To demonstrate that pyruvate can be transported against a proton gradient, we measured pyruvate efflux at acidic pH. In standard buffer at pH 5.0, pyruvate efflux was only reduced by 21 % (to 369p14 nmol\min per mg), suggesting that pyruvate can be transported against a significant proton gradient ( Figure 9B ).
DISCUSSION
We have demonstrated for the first time that proton efflux in T. brucei bloodstream forms is substantial, and sensitive to inhibitors of pyruvate transport (Table 4) . Inhibition of pyruvate efflux and proton efflux by pyruvate analogues in bloodstream forms was highly correlated (r# l 0.83), supporting the cotransport of protons and pyruvate by the plasma membrane pyruvate carrier in this stage (Table 4) . Additionally, inhibition of proton efflux by inhibitors of pyruvate transport led to significant cytosolic acidification, supporting a role for the pyruvate carrier in the regulation of pH i (Table 3) . pH i , proton efflux and pyruvate efflux were substantially decreased by the H + -ATPase inhibitor DCCD, but not by NEM or DES, suggesting that the primary effect of DCCD in bloodstream forms is on the pyruvate carrier and not on the H + -ATPase (Table 2 ; Figures 3, 6 and 9). However, when proton efflux was decreased by the omission of glucose ( Figure 6B ) or the addition of pyruvate ( Figure 6C ), a significant additional decrease in proton efflux could be observed on addition of DCCD, or of NEM or DES (results not shown). This suggests the presence of a plasma membrane H + -ATPase in bloodstream forms, which plays only a minor role in proton efflux and regulation of pH i when the pyruvate carrier is active. In procyclic forms, we determined that an H + -ATPase is the major regulator of pH i (Table 2 ; Figure 3 ) and proton efflux (Figure 4 ), based on sensitivity to H + -ATPase inhibitors.
We found pyruvate efflux to be inhibited by a number of pyruvate analogues, in close agreement with the results of pyruvate uptake experiments by Weimer et al. [8] , but less so with the results of pyruvate efflux experiments by Barnard et al. [9] . We noted slight decreases in pH i , proton efflux and pyruvate efflux in the presence of 25 mM lactate, whereas Weimer et al. [8] reported no effect on pyruvate uptake. We also noted no effect with 25 mM citrate, in agreement with Weimer et al. [8] , whereas Barnard et al. [9] observed a 29 % inhibition of efflux with 1.2 mM citrate. We also noted a significant effect of 2 mM α-CHC, in agreement with Barnard et al. [9] but not with Weimer et al. [8] . Many of the pyruvate analogues are extremely acidic and must be neutralized with base before use, and this may have contributed to the observed differences if this procedure was not carried out in other studies. The marked inhibitory effects of β-hydroxypyruvate and 3-bromopyruvate in bloodstream forms suggest that these analogues may be affecting more than just pyruvate transport. Additionally, β-hydroxypyruvate had significant effects on procyclic forms as well. Furthermore, Barnard et al. [9] found that not only did 3-bromopyruvate compete at the carrier with pyruvate, it was actively transported into the parasite, where it significantly and selectively inhibited trypanosomal glyceraldehyde-3-phosphate dehydrogenase.
We found that pyruvate efflux was significantly inhibited by the H + -ATPase inhibitor DCCD and by the anion-carrier blocker H # DIDS. Neither of these findings are without precedent, as Barnard et al. [9] noted that 100 µM DCCD or 100 µM DIDS reduced pyruvate efflux in bloodstream forms by 22 % and 14 % respectively, although they felt this decrease to be insignificant. Since H # DIDS is a known inhibitor of plasma membrane monocarboxylate transporters and DCCD is known to block H + transporters, it is reasonable to believe that these inhibitors could be affecting the pyruvate proton symporter [35, 37] . Previous studies in bloodstream forms have demonstrated sensitivity to DCCD and H # DIDS, which was interpreted to imply the involvement of an H + -ATPase and an anion carrier in the regulation of pH i [15] . However, it appears that at least some of the observed changes may result from direct inhibition of the pyruvate carrier.
Our calculated rate of pyruvate efflux (499 nmol\min per mg of protein) is considerably higher than previously published values for bloodstream forms (214 nmol\min per mg [9] ). However, Barnard et al. [9] performed their experiments at room temperature, and we noted a marked increase in pyruvate efflux at 37 mC compared with that at room temperature (results not shown). Additionally, our calculated rate of proton efflux (534 nmol\min per mg) agrees well with the rate of pyruvate efflux, assuming a 1 : 1 ratio of pyruvate to protons plus additional efflux from an H + -ATPase. Furthermore, Seyfang and Duszenko [4] measured glucose uptake in bloodstream forms at 37 mC of 252 nmol\min per mg of protein, which, if converted into two pyruvate molecules per glucose molecule, would approximate very closely to our values.
Since bloodstream forms rely almost exclusively on glycolysis, drugs that inhibit key components of this pathway potentially have potent trypanocidal activity. However, recent modelling studies have suggested that uncompetitive inhibition of pyruvate export by the pyruvate carrier is the only step in the metabolic pathway of glucose in T. brucei bloodstream forms that would increase the concentration of a metabolite sufficiently to interfere with the viability of the organism [38] . Additionally, it appears that the pyruvate carrier in bloodstream forms has a limited affinity for lactate, in contrast with many mammalian plasma membrane monocarboxylate carriers, which transport lactate in preference to pyruvate [39] . Furthermore, Barnard et al. [9] have demonstrated that the pyruvate carrier of T. brucei can efficiently transport toxic analogues of pyruvate that affect metabolic processes, as exemplified by the effect of 3-bromopyruvate on glyceraldehyde-3-phosphate dehydrogenase. It should be poss- ible, therefore, to exploit the differences in affinities between the bloodstream-form pyruvate carrier and the mammalian monocarboxylate transporter in the design of drugs that have a greater affinity for the parasite carrier. These drugs could inhibit pyruvate release directly, resulting in the build-up of pyruvate, acidification of the cytosol and inhibition of glycolysis, or they could be toxic pyruvate analogues that preferentially gain access to the parasite via the carrier and react with a critical metabolic enzyme [9, 10, 38] .
